Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1490469
European Journal of Endocrinology, Vol 149, Issue 6, 469-477
Copyright © 2003 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ntais, C
Right arrow Articles by Tsatsoulis, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ntais, C
Right arrow Articles by Tsatsoulis, A

Articles

Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes

C Ntais, A Polycarpou, and A Tsatsoulis

Division of Endocrinology, Department of Internal Medicine, University of Ioannina School of Medicine, Ioannina 45110, Greece.

In most western countries prostate cancer is the most commonly diagnosed non-skin cancer in men. Despite its high morbidity and mortality the etiology of prostate cancer remains obscure. The involvement of androgens has been examined extensively in prostate carcinogenesis but the results of most epidemiological studies remain inconclusive. This review focuses on current perspectives of androgen levels and polymorphisms in androgen-related genes. Racial differences in genetic polymorphisms that have a role in the biosynthesis and metabolism of androgens may partly account for racial differences in prostate cancer risk. Reasons are also given for inconsistent results in molecular epidemiological studies and insights and directions for future research are discussed. The development of a polygenic model for prostate cancer, incorporating multiple loci from the individual genes, may maximize the chance of identifying individuals with high-risk genotypes, resulting in better preventive, diagnostic, and therapeutic strategies.


This article has been cited by other articles:


Home page
Hum Mol GenetHome page
M. A. Albertelli, O. A. O'Mahony, M. Brogley, J. Tosoian, M. Steinkamp, S. Daignault, K. Wojno, and D. M. Robins
Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice
Hum. Mol. Genet., January 1, 2008; 17(1): 98 - 110.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
V. W. Setiawan, F. R. Schumacher, C. A. Haiman, D. O. Stram, D. Albanes, D. Altshuler, G. Berglund, J. Buring, E. E. Calle, F. Clavel-Chapelon, et al.
CYP17 Genetic Variation and Risk of Breast and Prostate Cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2237 - 2246.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
U. Moehren, M. Papaioannou, C. A. Reeb, W. Hong, and A. Baniahmad
Alien Interacts with the Human Androgen Receptor and Inhibits Prostate Cancer Cell Growth
Mol. Endocrinol., May 1, 2007; 21(5): 1039 - 1048.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. I. Berndt, N. Chatterjee, W.-Y. Huang, S. J. Chanock, R. Welch, E. D. Crawford, and R. B. Hayes
Variant in Sex Hormone-Binding Globulin Gene and the Risk of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 165 - 168.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Hietala, T. Sandberg, A. Borg, H. Olsson, and H. Jernstrom
Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women
Hum. Reprod., January 1, 2007; 22(1): 83 - 91.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Lindstrom, F. Wiklund, H.-O. Adami, K. A. Balter, J. Adolfsson, and H. Gronberg
Germ-Line Genetic Variation in the Key Androgen-Regulating Genes Androgen Receptor, Cytochrome P450, and Steroid-5-{alpha}-Reductase Type 2 Is Important for Prostate Cancer Development.
Cancer Res., November 15, 2006; 66(22): 11077 - 11083.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
N. L. Nock, M. S. Cicek, L. Li, X. Liu, B. A. Rybicki, A. Moreira, S. J. Plummer, G. Casey, and J. S. Witte
Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk
Carcinogenesis, September 1, 2006; 27(9): 1842 - 1848.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. Baida, S. M. Farrington, P. Galofre, R. Marcos, and A. Velazquez
Thyroid Cancer Susceptibility and THRA1 and BAT-40 Repeats Polymorphisms
Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 638 - 642.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. L. Parnes, I. M. Thompson, and L. G. Ford
Prevention of Hormone-Related Cancers: Prostate Cancer
J. Clin. Oncol., January 10, 2005; 23(2): 368 - 377.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. Ntais, A. Polycarpou, and J. P.A. Ioannidis
Association of GSTM1, GSTT1, and GSTP1 Gene Polymorphisms with the Risk of Prostate Cancer: A Meta-analysis
Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 176 - 181.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Zitzmann, M. Depenbusch, J. Gromoll, and E. Nieschlag
X-Chromosome Inactivation Patterns and Androgen Receptor Functionality Influence Phenotype and Social Characteristics as Well as Pharmacogenetics of Testosterone Therapy in Klinefelter Patients
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6208 - 6217.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 European Society of Endocrinology.